D-Pharmâ€™s VP for Clinical Development, Dr. Gilad Rosenberg added; â€œIâ€™m happy to be involved in this clinical trial that may ultimately benefit stroke patients and Iâ€™m looking forward to swift patient enrolment.
Similarly, THR-18 reduced by more than twice the occurrence of brain edema (p Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development commented, "It is certainly encouraging to see the reduced rates of brain swelling and intracranial bleeding in the tPA-treated stroke patients given THR-18, and I look forward to see whether these findings translate into less disability and better neurological recovery once the clinical endpoint data become available for the full data set."
Dr Gilad Rosenberg, VP Clinical Development at D-Pharm added: "We are very encouraged by the fact that this is the second Phase II clinical study in which we observe beneficial effects of DP-b99 on ischemic stroke outcomes.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.